Strategy and business model (QCA Principle 1)

ANGLE is a world-leading liquid biopsy company commercialising a platform technology that can capture cells circulating in blood, such as circulating tumour cells (CTCs), intact living cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE’s cell separation technology is called the Parsortix system and is the subject of granted patents in multiple jurisdictions. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility.

The analysis of the cells that can be harvested from patient blood with ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

ANGLE’s vision is to secure widespread adoption of the Parsortix system by providing CTCs as the “best sample” for analysis coupled with state-of-the-art molecular assays to provide high-throughput, low cost, highly sensitive, downstream multi-omic analysis. To drive commercialisation, ANGLE has established both a product business and a services business

1. Product business area

ANGLE’s Parsortix system including instruments and one-time use cassettes, that are sold to third-party laboratories for their use in research, pharmaceutical development, and clinical use. In December 2023, ANGLE’s quality management system was re-certified as meeting ISO/EN/BSI 13485:2016 with the exemplary condition of our laboratories commended. To enable customers to carry out downstream analysis of the Parsortix harvest, ANGLE now offers the Portrait+ CTC Staining Kit and the CellKeep Slide for enhanced cell recovery and imaging. ANGLE will continue to develop further assay kits and protocols for third-party molecular platforms.

2. Services business area

ANGLE has established a GCLP-compliant clinical laboratory in the UK, with the capability, capacity and required quality systems to provide biopharma customers with assay services to support clinical drug development. In the longer term, ANGLE’s clinical laboratory will process patient samples and offer validated assays to support clinical decision making.

Both business areas are supported by a growing body of internal and published evidence and content from leading cancer centres showing the utility of the system through peer-reviewed publications, scientific data and clinical research evidence, highlighting a wide range of potential applications.